Cappella Medical Devices
Home
Cappella Medical Devices
Cappella, Inc. – a medical device company specialising in cardiovascular innovations –
has developed the Sideguard® Coronary Sidebranch Stent & Delivery System, offering
interventional cardiologists a novel solution for the treatment of coronary bifurcation disease.
Sideguard® – Cappella’s initial product – consists of a uniquely designed self-expanding nitinol coronary stent that makes use of a novel, balloon-catheter, split-sheath delivery system. Both the stent and the delivery system were developed by Cappella Medical Devices Ltd., the R&D and manufacturing subsidiary of Cappella, Inc.
CE-marked in April 2009, Cappella’s Sideguard® offers a new, simple and effective option for treating bifurcation disease, with a focus on treating the sidebranch of the diseased coronary artery first, rather than the main vessel. Moreover, the Sideguard® system allows the preferred stent of choice for the main vessel.
The Sideguard® stent is used in combination with a novel, low-profile balloon-catheter delivery system, which enables straightforward, rapid-exchange delivery and precise stent placement at the sidebranch ostium. During positioning, a sheath encloses the stent; however, once the stent is in place, the delivery system balloon is inflated, and in doing so, the sheath is split and the stent released. The delivery system is then withdrawn, leaving the stent in place. This proprietary split-sheath technology prevents the stent jumping at delivery and ensures accurate deployment of the device.
Bifurcation procedures are complicated, not least owing to the complex and variable anatomy of the coronary ostia. The Sideguard® stent itself is uniquely designed to conform to the anatomy of the sidebranch ostium, and while the elastic property of nitinol enables the stent to self expand so as to adapt to the various ostial morphologies, the mechanical property of nitinol sustains continuous wall apposition and scaffolding. The stent is thus able to dynamically appose the full lumen of the sidebranch, including the ostium. This dynamic apposition results in continuous contact between the stent and the vessel wall, as well as arterial expansion (positive remodelling) over time.
The Sideguard® Coronary Sidebranch Stent & Delivery System offers interventional cardiologists a dynamic new option for treating bifurcation disease. This unique product demonstrates that good product design is able to provide benefits that can be seen in the clinic.
Sideguard® – Cappella’s initial product – consists of a uniquely designed self-expanding nitinol coronary stent that makes use of a novel, balloon-catheter, split-sheath delivery system. Both the stent and the delivery system were developed by Cappella Medical Devices Ltd., the R&D and manufacturing subsidiary of Cappella, Inc.
CE-marked in April 2009, Cappella’s Sideguard® offers a new, simple and effective option for treating bifurcation disease, with a focus on treating the sidebranch of the diseased coronary artery first, rather than the main vessel. Moreover, the Sideguard® system allows the preferred stent of choice for the main vessel.
The Sideguard® stent is used in combination with a novel, low-profile balloon-catheter delivery system, which enables straightforward, rapid-exchange delivery and precise stent placement at the sidebranch ostium. During positioning, a sheath encloses the stent; however, once the stent is in place, the delivery system balloon is inflated, and in doing so, the sheath is split and the stent released. The delivery system is then withdrawn, leaving the stent in place. This proprietary split-sheath technology prevents the stent jumping at delivery and ensures accurate deployment of the device.
Bifurcation procedures are complicated, not least owing to the complex and variable anatomy of the coronary ostia. The Sideguard® stent itself is uniquely designed to conform to the anatomy of the sidebranch ostium, and while the elastic property of nitinol enables the stent to self expand so as to adapt to the various ostial morphologies, the mechanical property of nitinol sustains continuous wall apposition and scaffolding. The stent is thus able to dynamically appose the full lumen of the sidebranch, including the ostium. This dynamic apposition results in continuous contact between the stent and the vessel wall, as well as arterial expansion (positive remodelling) over time.
The Sideguard® Coronary Sidebranch Stent & Delivery System offers interventional cardiologists a dynamic new option for treating bifurcation disease. This unique product demonstrates that good product design is able to provide benefits that can be seen in the clinic.
Contact Details
Unit 3, Ballybrit Business ParkBallybrit
Galway
Tel:
+353 (0) 91 758939
Fax: +353 (0) 91 758930
contact: info@cappella.ie
website: www.cappella-med.com
Fax: +353 (0) 91 758930
contact: info@cappella.ie
website: www.cappella-med.com
Keywords:
coronary stent, invasive cardiology, acapella medical device, coronary arteries, drug eluting stent, stent restenosis, eluting coronary stent, stent thrombosis
Related categories:
Device Companiescoronary stent, invasive cardiology, acapella medical device, coronary arteries, drug eluting stent, stent restenosis, eluting coronary stent, stent thrombosis
Sideguard®Coronary Sidebranch Stent - Details
Sideguard® Coronary Sidebranch Stent
Device & System Details
| Device Profile: | 3.2 Fr (recommended 7 Fr guiding catheter); Crossing profile (.0417") |
| Delivery System: | Rapid-exchange, balloon-activated split-sheath catheter system |
| Stent Size: | 2.5 (lumen size 2.25-2.50mm) 2.75 (lumen size 2.50-2.75mm) 3.25 (lumen size 2.75-3.25mm) |
| Stent Length: | 10mm (lesion length ≤ 7mm) |
| Stent Design: | Self-expanding nitinol (64µm struts); 3-segment stent: trumpet, gimbal, & anchor |
Keywords:
intimal hyperplasia, intravascular ultrasound, coronary arteries, balloon catheter, nitinol stent, precise stent, left main coronary artery disease
Sideguard® Design
Sideguard® Design
A variable sidebranch ostium anatomy requires a unique solution and an optimal stent design. The Sideguard® is designed to ensure continuous wall apposition. The components are:
- Trumpet – conforms to sidebranch ostium
- Gimbal – provides expansion force to open sidebranch
- Anchor – designed to avoid stent migration
The Sideguard® stent therefore dynamically apposes the full sidebranch lumen including the ostium. This dynamic apposition results in continuous stent to vessel wall contact as well as an increase in vessel diameter over time.
![]() | Trumpet – conforms to sidebranch ostium Gimbal – provides expansion force to open sidebranch Anchor – designed to avoid stent migration Sideguard® is designed to ensure continuous wall apposition | |
![]() Proprietary split-sheath technology | ![]() Stent fully deployed with wall apposition | ![]() Main vessel stent combined with Sideguard® |
Keywords:
coronary arteries, intravascular ultrasound, stent placement, coronary stent, drug eluting stent, left anterior descending, balloon angioplasty
Upcoming Events
Keywords:
Jim 2010, EuroPCR2010, Deutsche Gesellschaft für Kardiologie (DGK), PCI Seminar , bifurc.net, TCT 2010
Press Releases
Press Releases
Cappella Promotes Sideguard & Serial IVUS Analysis at JIM 2010 [19 February 2010]
GALWAY, Ireland-- Cappella, Inc. (Cappella), a medical device company developing dynamic solutions for the treatment of coronary bifurcation disease, promoted their serial IVUS analysis & Sideguard® 3.25 device during the Joint Interventional Meeting (JIM) in Rome. Gary S. Mintz, MD, Cardiovascular Research Foundation, New York, USA presented “Positive Vessel Remodeling Using Sideguard in Coronary Bifurcations” during the New Technologies 1 Symposium. Dr. Mintz highlighted that serial IVUS & OCT are ongoing in the Sideguard 3 study to confirm the initial findings of Sideguard 1 and assess stent strut coverage. The IVUS sub-study results from Sideguard 1 were published in the American Journal of Cardiology in October 2009.
Eamonn Hobbs joins the Board of Directors at Cappella [17 February 2010]
GALWAY, Ireland-- Cappella, Inc. (Cappella), a medical device company developing dynamic solutions for the treatment of coronary bifurcation disease, announced the addition of Mr. Eamonn Hobbs to the Board of Directors. According to Mr. Wolfgang Oster, MD, PhD, Chairman of the Board and Managing Partner at PolyTechnos Venture-Partners GmbH, “Eamonn’s wealth of expertise and solid track record of success in our medical device field makes him a formidable source of wisdom and judgement for the road ahead of Cappella. The company’s commercial programs and global market expansion will greatly benefit from Mr Hobbs’ insights.”





























